IDXX Stock: Price, Earnings History and SEC Filings
IDEXX Laboratories, Inc. (IDXX) last traded at $551.21, down 4.30% on the latest session and up 5.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $4.27 against an analyst estimate of $3.95, a beat of 8.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IDXX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $4.27 | $3.95 | +8.10% |
| Mar 2026 | May 5, 2026 | $3.47 | $3.42 | +1.46% |
| Dec 2025 | Feb 2, 2026 | $3.08 | $2.93 | +5.12% |
| Sep 2025 | Nov 3, 2025 | $3.40 | $3.14 | +8.28% |
IDXX beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How IDXX reacts to earnings
Across its last 8 earnings releases, IDXX moved 10.1% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | Before open | +3.57% |
| 2026-05-05 | Before open | -0.03% |
| 2026-02-02 | Before open | -4.60% |
| 2025-11-03 | Before open | +14.84% |
| 2025-08-04 | Before open | +27.49% |
| 2025-05-01 | Before open | +8.95% |
| 2025-02-03 | Before open | +11.13% |
| 2024-10-31 | Before open | -9.79% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
IDXX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $4.3B | $1.1B | $1.1B | 24.6% | $13.08 |
| 2024 | $3.9B | $888M | $808M | 22.8% | $10.67 |
| 2023 | $3.7B | $845M | $773M | 23.1% | $10.06 |
| 2022 | $3.4B | $679M | $394M | 20.2% | $8.03 |
| 2021 | $3.2B | $745M | $636M | 23.2% | $8.60 |
| 2020 | $2.7B | $582M | $541M | 21.5% | $6.71 |
| 2019 | $2.4B | $428M | $304M | 17.8% | $4.89 |
| 2018 | $2.2B | $377M | $284M | 17.0% | $4.26 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for IDXX
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · May 15, 2026Bylaw change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Mar 27, 2026
- 8-K · Mar 26, 2026Officer or director change, Financial statements and exhibits
- 10-K · Feb 20, 2026
- 8-K · Feb 13, 2026Officer or director change
- 8-K · Feb 2, 2026Results of operations, Financial statements and exhibits
Insider filing activity
IDXX insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
IDXX news
- IDEXX Laboratories (IDXX) Stock Looks Fairly Valued Despite Its 28% RunOct 31, 2026 · finance.yahoo.com
- Cencora Gears Up to Report Q4 Results: How to Play the Stock?Oct 30, 2026 · finance.yahoo.com
- Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?Oct 30, 2026 · finance.yahoo.com
- STERIS Set to Report Q2 Earnings: What's in the Cards for the Stock?Oct 30, 2026 · finance.yahoo.com
- IDEXX Laboratories Reports Soon: How Has The Stock Reacted To Past Earnings?Oct 30, 2026 · trefis.com
- Zoetis (ZTS) vs. IDXX and ELAN: Is Valuation Compression Creating a Rare Opportunity in Animal Health?Oct 29, 2026 · finance.yahoo.com
- BTSG Ahead of Q3 Earnings: Can Growth Offset Ongoing IRA Risks?Oct 29, 2026 · finance.yahoo.com
- Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?Oct 29, 2026 · finance.yahoo.com
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. (IDXX) is a US-listed public company on Nasdaq. The SEC classifies its business as In Vitro & In Vivo Diagnostic Substances. It is incorporated in DE. Its fiscal year ends in December.